THE Global. Last March 12 marked the 10th anniversary of the approval of the first biosimilar in the European Union. It was the growth hormone Omnitrope (Somatropin), from Sandoz, whose reference biological was Genotropin, from Pfizer. From then until today there are already 20 biosimilars available in the European Union. But there is still a long way to go and it is expected that the next few years will be key in the launch of new biosimilars to the market. This is how the employers Medicines for Europe considers it, which, in the white paper Delivering on the Potential of Biosimilar Medicines: the Role of Functioning Competitive Markets, published recently, aims to launch more than 50 new biosimilars by 2020.

READ MORE